Target intelligence / Profile preview

Human T-cell leukemia virus type 1 envelope glycoprotein gp46 proline-rich region (HTLV-1 gp46 PRR)

Target
HTLV-1 gp46 PRR
Molecular classification
Viral envelope protein, Glycoprotein, Surface subunit (SU)
01

Overview

The Human T-cell leukemia virus type 1 (HTLV-1) envelope glycoprotein gp46 is the surface (SU) subunit responsible for viral attachment and entry into host T-cells. Within gp46, the central proline-rich region (PRR) serves as a critical flexible linker between the N-terminal receptor-binding domain and the C-terminal domain (UniProt P03381). This region is essential for transmitting the signal of receptor binding to the transmembrane subunit (gp21), thereby triggering the conformational changes required for membrane fusion (Garrus et al., J Virol, 2000). As a highly conserved and immunodominant segment, the PRR is a major target for neutralizing antibodies that can block viral infection and syncytium formation (Pique et al., J Virol, 1992). Therapeutic strategies focusing on this region include the development of monoclonal antibodies and subunit vaccines intended to prevent or treat HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) and Adult T-cell leukemia/lymphoma (ATL) (Kim et al., J Biol Chem, 2004).

Other names
HTLV-1 gp46 central regionHTLV-1 SU proline-rich regionSurface glycoprotein gp46 PRRgp46 hinge region
02

Mechanism of action

Neutralization of viral particles, inhibition of viral entry into host cells, and prevention of syncytia formation by blocking conformational changes required for membrane fusion.

03

Biological functions

Viral entryMembrane fusionReceptor bindingConformational signalingViral attachment
04

Disease associations

Adult T-cell leukemia/lymphoma (ATL)HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)HTLV-1 infectionInfective dermatitis
05

Safety considerations

Viral mutation leading to immune evasionLow immunogenicity of specific linear epitopesPotential for antibody-dependent enhancement (ADE)Challenges in targeting latent viral reservoirs
06

Interacting drugs

LAT-27 (Experimental monoclonal antibody)

3 more in the full profile.

07

Biomarkers

HTLV-1 proviral loadAnti-gp46 antibody titersgp46 antigen levels

Beyond the preview

Go deeper on Human T-cell leukemia virus type 1 envelope glycoprotein gp46 proline-rich region (HTLV-1 gp46 PRR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human T-cell leukemia virus type 1 envelope glycoprotein gp46 proline-rich region (HTLV-1 gp46 PRR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call